IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110653 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Mengya Jiao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic I…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, HMGB1 Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Interleukin-33 (IL-33) and high mobility group box 1 (HMGB1) have been reported to play crucial and distinct roles in experimental autoimmune encephalomyelitis (EAE). However, little is known about their interaction in the progression of EAE. In this study, the dynamic expression and release of IL-33 and HMGB1 in different stages of EAE in vivo, and their interaction in vitro were explored. We found that HMGB1 was dominant in pre-onset stage of EAE, while IL-33 was dominant in peak stage. Moreover, both blockade of extracellular HMGB1 in the central nervous system (CNS) and conditional knockout of HMGB1 in astrocytes decreased IL-33 release. HMGB1 promoted the release of IL-33, while IL-33 reduced the release of HMGB1 from primary astrocytes in vitro. Taken together, IL-33 and HMGB1 in the CNS jointly participate in the EAE progression and the inhibitory effect of IL-33 on HMGB1 may be involved in the self-limiting of EAE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology, Wuha…
- Wuhan Institute for Neuroscience and Neuroengineering, South-Central Minzu University, Wuhan 430074, China; College of Life Sciences, South-Central Minzu University, Wuhan 430074, China.
- Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China.
- College of Life Science, Yangtze University, Jingzhou 434025, China.
- National Demonstration Center for Experimental Basic Medical Education, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: wangchenj…
- Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China; Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affili…
Zitieren
APA
Jiao, M., Sun, Y., Shi, J., Zhang, N., Tang, X., Fan, A., Liu, S., Dai, C., Qian, Z., Zhang, F., Wang, C., Chen, H., & Zheng, F. (2023). IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110653
Vancouver
Jiao M, Sun Y, Shi J, Zhang N, Tang X, Fan A, et al. IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110653
BibTeX
@article{Jiao2023,
author = {Jiao, Mengya and Sun, Yan and Shi, Junyu and Zhang, Na and Tang, Xuhuan and Fan, Anqi and Liu, Shiwang and Dai, Chan and Qian, Zhigang and Zhang, Feng and Wang, Chenchen and Chen, Huoying and Zheng, Fang},
title = {IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110653}
}
EUVIMED